CAPPS VICKIE L 4

What Happened

• Janux Therapeutics director Vickie L. Capps received two non‑cash awards on 2026-06-11: 5,500 restricted stock units (RSUs) and a 15,500-share derivative award (an equity award/option). Both were granted at $0.00 (no cash purchase); total reported acquisition value = $0.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (appears timely).
• Prices: both grants reported at $0.00 per share; reported acquisition amounts = $0.
• Vesting/derivative notes:
  • The 5,500 RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continuous service (Footnote F1).
  • The 15,500-share derivative award vests in equal monthly installments over the 12 months after June 11, 2026, and in any event will be fully vested by the next annual meeting, subject to continuous service (Footnote F2).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: filing date is the day after the report date (not indicated as late).

Context

• These are grants/awards (A) — not open‑market purchases or sales — so they reflect compensation/equity incentives rather than an insider buying or selling shares in the market.
• The derivative award appears to be a time‑based grant (option or similar) that vests over 12 months; such awards are common for directors and typically require continued service to vest.